Generalized Pustular Psoriasis Market Insight, Epidemiology, and Market Forecast Analysis Report

Generalized Pustular Psoriasis Market Insight, Epidemiology, and Market Forecast Analysis Report What is Generalized Pustular Psoriasis Market? Generalized Pustular Psoriasis (GPP) is a subtype of pustular psoriasis characterized by painful and occasionally disfiguring cutaneous manifestations with sepsis-like systemic symptoms. Generalized Pustular Psoriasis Epidemiology  A higher percentage of diagnosed Generalized Pustular Psoriasis prevalence was observed for females, in comparison to males.  The total diagnosed prevalent Population of Generalized Pustular Psoriasis in the 7MM was assessed to be more than 14,000 in 2017.  The highest diagnosed Generalized Pustular Psoriasis prevalence in the United States with close to 6,000 cases in 2017.  Japan had 2,602 prevalent cases for Generalized Pustular Psoriasis in 2017. Generalized Pustular Psoriasis Market Outlook According to DelveInsight, Generalized Pustular Psoriasis market in 7MM is expected to change in the study period 2017-2030. The current Generalized Pustular Psoriasis therapeutic landscape in the United States is driven by supportive therapies (topical therapies, systemic therapies, biologics, and phototherapy). In EU-5 countries, for GPP, the market is the same as that of the US, with prescriptions for supportive therapies, due to lack of approved treatment regimens. In contrast to the US and EU-5 countries, the current therapeutic landscape of GPP in Japan is driven by a number of approved therapies, along with supportive treatment regimens. A modest increase in the Generalized Pustular Psoriasis market size of currently prescribed therapies has been witnessed from 2017 until the launch of emerging therapies in respective countries. The market share is expected to decline post that for current therapies, across the 7MM, owing to the increasing demand for targeted therapies to treat GPP. Among the current treatment regimens, biologics occupy the highest number of prescriptions in the treatment market of GPP. Moreover, combination therapies remain the mainstay in the treatment of GPP, irrespective of the severity of the disease. The current therapeutic landscape of GPP in the US and EU-5 countries is primarily driven by supportive treatment regimens, such as topical therapies, phototherapy, oral systemic therapies, and Biologics. Depending on the severity of the symptoms, prescription medications may vary among patients. According to National Psoriasis Foundation, United States, the first-line treatment regimens for GPP recommended according to treatment standards include one or a combination: Secukinumab, Brodalumab, Cyclosporine, Methotrexate, Infliximab, Ixekizumab, Guselkumab, and Systemic retinoids, such as acitretin. The market size of approved therapies in Japan [Tremfya (Janssen Pharmaceutical); SKYRIZI (AbbVie/Boehringer Ingelheim); HUMIRA (AbbVie/Eisai); Lumicef (Kyowa Hakko Kirin); COSENTYX (Novartis); Remicade (Mitsubishi Tanabe Pharma); and Ixekizumab (Eli Lilly)] has been assessed based on the category of the drug, i.e. all of these approved regimens belong to the class of biological drugs.

Therefore, we have assessed the cumulative contribution of all biologics in Japan, including the aforementioned drugs. The high unmet needs associated with the disease have driven vendors to conduct R&D, which has fueled the pipeline, particularly for the treatment of GPP. The launch of few multiple-stage pipeline products will definitely dominate the use of off-label products that are being currently used, in the near future. As such, the number of clinical trials for GPP is increasing and their success rate has also increased the chances that commercial approval of different GPP therapeutics will be received by industries during the forecast period. It is believed that the pipeline drugs, which are in the clinical stage of development of different forms of GPP can be superior to the off-label therapies, in terms of clinical and commercial profiles. Which biotechnological companies involved in the development of Generalized Pustular Psoriasis therapies? Boehringer Ingelheim, AnaptysBio, Mitsubishi Tanabe Pharma, Eli Lilly & Company, AbbVie/Eisai, Kyowa Hakko Kirin, Novartis, Janssen Pharmaceuticals, and others are involved in the development of Generalized Pustular Psoriasis therapies. Request sample pages for more information on Generalized Pustular Psoriasis Market Size